Background alzheimers Shape Background alzheimers Shape Background alzheimers Shape
Grants > Presenilin in Neurodegeneration: Role of Akt/ERK Pathways Updated On: Jan. 19, 2025
Alzheimer's Disease Research Grant

Presenilin in Neurodegeneration: Role of Akt/ERK Pathways

BFF logo

Principal Investigator

David Kang, PhD

University of California, San Diego

La Jolla, CA, USA

About the Research Project

Program

Alzheimer's Disease Research

Award Type

Standard

Award Amount

$297,819

Active Dates

April 01, 2005 - June 30, 2007

Grant ID

A2005039

Summary

Inherited mutations in two similar genes, presenilin 1 (PS1) and presenilin 2 (PS2), cause the most aggressive forms of AD with disease onset between 30 to 60 years of age. It is widely believed that these genes cause AD by accelerating amyloid plaque deposition in the brain. Growing evidence has found that presenilin dysfunctions may also drive tangle pathology independent of the effects from amyloid plaques. This finding is significant, because many therapeutic agents currently under development are designed to reduce amyloid plaques by inhibiting the functions of both PS1 and PS2. These agents may end up inadvertently promoting nerve damage and tangle formation instead. It is important to understand whether mutations in PS1 or PS2 can influence nerve damage and tangle formation independent of the effects associated with amyloid plaques. Experimental data has indicated that 2 molecular pathways (Akt and ERK) important for nerve cell survival are severely compromised in cells lacking both PS1 and PS2. Dr. Kang plans on testing whether delivery of activated Akt or ERK genes can prevent brain damage.